Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - (Details Narrative)

v3.21.1
Stock-Based Compensation - (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
May 14, 2021
Apr. 02, 2021
Mar. 01, 2021
May 01, 2020
May 01, 2020
Mar. 15, 2019
Mar. 31, 2021
Mar. 31, 2020
Proceeds from issuance of common stock             $ 55,016
General and administrative expense             3,375 2,240
Research and development expense             3,315 2,628
Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]                
Stock-based compensation expense             805 16
Employee Stock Purchase Plan [Member]                
Proceeds from issuance of common stock             $ 304 $ 126
Number of stock purchase of common stock             203,480 154,266
Number of common stock reserved             750,000  
Employee Stock Purchase Plan [Member] | Maximum [Member] | Board of Directors [Member]                
Increase in stock options available-for-grant             157,153  
2014 Equity Plan [Member]                
Stock options available-for-grant             1,679,239  
Increase in stock options available-for-grant             500,854  
Weighted average fair value of stock options             $ 2.79 $ 1.34
General and administrative expense             $ 185 $ 62
Research and development expense             $ 38 $ 38
2014 Equity Plan [Member] | Restricted Stock [Member]                
Number of restricted stock award granted       950,000 950,000 700,000    
Vesting portion of stock       2014 Equity Plan, vesting as follows: 450,000 restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021   2014 Equity Plan, vesting as follows: 233,334 restricted stock awards vested on March 15, 2020; and 466,666 restricted awards vesting on March 15, 2022.    
Restricted stock awards vested       450,000   233,334    
Stock-based compensation expense         $ 1,938 $ 742    
2014 Equity Plan [Member] | Restricted Stock [Member] | May 1, 2023 [Member]                
Restricted stock awards vested       500,000        
2014 Equity Plan [Member] | Restricted Stock [Member] | March 15, 2022 [Member]                
Restricted stock awards vested           466,666    
2014 Equity Plan [Member] | Subsequent Event [Member]                
Number of stock options granted 1,170,000              
Weighted average fair value of stock options $ 4.49              
2014 Equity Plan [Member] | Subsequent Event [Member] | Restricted Stock [Member]                
Number of restricted stock award granted   300,000            
2018 Stock Plan [Member]                
Stock options available-for-grant             2,265,000  
Number of common stock issued             3,333  
Proceeds from issuance of common stock             $ 5  
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]                
Restricted stock awards vested     1,040,000          
Offering scenario, description     A relative weighting of 75% was applied to the IPO scenario and 25% was assigned to the stay private scenario.          
Grant date fair value     $ 18,900,000          
2018 Equity Plan [Member] | Subsequent Event [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member]                
Number of restricted stock award granted 65,000